This Practice Point commentary discusses the study by Denzinger et al. in which patients with high-grade T1 (HGT1) bladder cancer were treated by transurethral resection with either white-light ...

Transurethral resection of bladder tumor (TURBT) certainly needs to be improved. As currently practised, TURBT is far from perfect—tumor is left unresected in about 30% of cases 3 despite major ...

When a doctor suspects bladder cancer, they will order a series of tests which may include urine tests (urinalysis or urine ...

Blue light cystoscopy reduces bladder cancer recurrence risk by 38% compared to white light cystoscopy, as shown in the BRAVO study. The BRAVO study used real-world data from 626 veterans, confirming ...

Non-muscle-invasive bladder cancer is labor intensive and costly to manage. Owing to long-term survival rates and life-long monitoring and treatment, it is the most expensive cancer to manage in ...

Accurate documentation of lesions during transurethral resection of bladder tumors (TURBT) is essential for precise diagnosis, treatment planning, and follow-up care. However, optimizing schematic ...

Background: A 59-year-old female presented with a history of recurrent superficial bladder cancer. Since the initial diagnosis 12 years earlier, she had had 12 recurrences, all treated with ...

In patients with suspected muscle-invasive bladder cancer (MIBC), definitive treatment can be expedited by adding multi-parametric magnetic resonance imaging (mpMRI) to flexible cystoscopic biopsy at ...

Hepatitis E Infection From Plasma Exchange Recommendations for diagnosing and managing non-muscle invasive bladder cancer promise to allow for more individualized patient care. Newly released clinical ...

Please provide your email address to receive an email when new articles are posted on . Transurethral resection of bladder tumor plus systemic therapy induced clinical complete response among a large ...